Navigation Links
Quark Pharmaceuticals to Present at American Society for Pharmacology and Experimental Therapeutics Annual Meeting
Date:4/20/2009

FREMONT, Calif., April 20 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that James D. Thompson, Ph.D., Vice President, Pharmaceutical Development, will give a presentation on Tuesday, April 20 at this year's American Society for Pharmacology and Experimental Therapeutics (ASPET) Annual Meeting, which is taking place from April 18-22, 2009 in New Orleans.

Dr. Thompson's presentation will be part of a session titled "Discovery and Development of Oligonucleotide Therapeutics," which is sponsored by ASPET's Divisions for Drug Discovery, Drug Development & Regulatory Affairs and Molecular Pharmacology. His talk will be on the past, present, and future of oligonucleotide therapeutics. Other leaders in RNAi will also present during the session including: Pamela A. Pavco, Vice President of Pharmaceutical Development at RXi Pharmaceuticals (topic: Special issues in the discovery and development of RNAi therapeutics); Christina Gamba-Vitalo, Senior Director Preclinical Development at Alnylam Pharmaceuticals (topic: Progress in developing siRNAs as drugs); and Patrick L. Iversen, Senior Vice President of Strategic Alliances and former Senior Vice President of Research and Development at AVI BioPharma (topic: Pharmacokinetics of oligonucleotide therapeutics).

Daniel Zurr, Ph.D., President and Chief Executive Officer of Quark, said, "We are pleased with Quark's participation in this session alongside respected leaders in RNAi development. The invitation reinforces that the drug development industry recognizes Quark's leadership position in siRNA development. Some of the Company's accomplishments include: a number of on-going clinical trials of synthetic siRNAs in various disease indications, status as the first company to administer a synthetic siRNA systemically in humans, an, enabling portfolio of I
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008
2. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
3. Quark Pharmaceuticals to Participate in 9th Annual Beyond Genome Conference
4. Mpex Pharmaceuticals Names Mark Wiggins Chief Business Officer
5. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
6. Sunesis Pharmaceuticals Receives NASDAQ Notification
7. Angiotech Pharmaceuticals, Inc. Announces Conference Call And Webcast
8. XTL Biopharmaceuticals Ltd. Receives Notification of Delisting Determination by NASDAQ Listing Qualifications Panel
9. Accera, Inc. Launches Neuera Pharmaceuticals, Inc.
10. Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Researchs 100th Annual Meeting
11. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... 02, 2014 IAL is pleased ... of its report on the markets for rigid ... examines the developments encountered in the global market ... , Full Report With TOC @ ... trends driving the demand. The study presents production ...
(Date:10/2/2014)... MO (PRWEB) October 02, 2014 Permian ... business in the St. Louis, Missouri, area on October ... has become a leading plastic injection molder in the ... machines and is a supplier to many Fortune 500 ... customer support every step of the way, from concept ...
(Date:10/2/2014)... de 2014 Laborie Medical Technologies, Inc. ("LABORIE"), ... ha completado la adquisición de Unisensor AG y Unisensor ... sede central sita en Wiesendangen, Suiza, y lleva a ... New Hampshire . Unisensor está especializada en el ... para evaluar la presión y valores de pH para ...
(Date:10/2/2014)... -- SIRO Clinpharm, an award-winning Clinical Research ... Annual Conference of the Society for Clinical Data Management ... where they were invited to speak at three sessions. ... to support fraud detection, ,clinical data management,s role in ... together as virtual and integrated teams,. The award-winning streak ...
Breaking Biology Technology:Global Overview of the Spray Polyurethane Foam (SPF) & One Component Foam (OCF) : Industry Analysis, Size, Share, Trends And Forecast Research Report by Researchmoz 2Permian Plastics LLC Celebrates 20 Years As Leading Manufacturer of Plastic Molds 2LABORIE adquiere Unisensor AG y Unisensor USA, Inc. 2SIRO Clinpharm Showcases Biometrics Capabilities at the SCDM 2014 Annual Conference in Las Vegas 2
... 15 MannKind,Corporation (Nasdaq: MNKD ), focused on ... today that it,will present at the UBS Global Life ... (ET) at the Grand Hyatt in New York., ... web cast of the,presentation in the Investor Relations section ...
... Join as Company Enters Commercialization Phase, NAPLES, ... TO ETHANOL(TM), the most advanced third generation biofuels,technology, ... with the,appointments Greg Schlicht as Senior Vice President ... as Senior Program Manager., Mr. Schlicht will ...
... Sept. 15 Insmed Inc. (Nasdaq:,INSM) a developer ... Allan, Ph.D., CEO of Insmed, will present at ... will be discussing,the Company,s perspective on the potential ... will also Chair a panel on this topic ...
Cached Biology Technology:Algenol Biofuels Further Strengthens Team With Key Appointments 2Insmed to Present at Biosimilars 2008 Conference 2
(Date:9/30/2014)... 2014--Sea monkeys have captured the popular attention of both ... life cycle -- sold as dehydrated eggs, these tiny ... more than a tank of salt water. , ... other zooplankton, brine shrimp vertically migrate in large groups ... the surface at night and retreating deeper during the ...
(Date:9/30/2014)... team of environmental scientists and engineers, led by ... a three-year, $5.25 million grant from the U.S. ... Research to make a direct positive impact on ... and disposal of radioactive contaminants. , "Understanding the ... dealing with environmental aspects of nuclear technologies is ...
(Date:9/30/2014)... can live in almost any aquatic environment on Earth, ... many species are pushed to the limit. The amount ... prove critical for how different species cope in the ... University of Gothenburg, published in the scientific journal ... change continues apace thanks to increasing levels of greenhouse ...
Breaking Biology News(10 mins):Laser-guided sea monkeys show how zooplankton migrations may affect global ocean currents 2Researchers get $5.25 million to advance nuclear technologies in South Carolina 2Shape up quickly -- applies to fish, too! 2
... the Bellvitge Biomedical Research Institute (IDIBELL) at the ... into how the IDPN nitrile causes neurological syndromes ... (ALS), a severe neuromuscular degenerative disease. The study, ... in Neuropathology and Applied Neurobiology journal. ...
... to dust off the garden tables and chairs. But garden furniture ... covered with a slimy film of algae, moss, bacteria and fungi ... hoping that they can solve this problem by incorporating titanium dioxide ... adding a little bit of sunlight. When these titanium dioxide molecules ...
... German . Zebrafish share most organ systems ... the causes of human diseases like cancer or heart diseases. ... With the European Zebrafish Resource Center (EZRC), Karlsruhe Institute of ... such lines in Europe. The EZRC is funded jointly by ...
Cached Biology News:Poisoning from industrial compounds can cause similar effects to ALS 2Cleaning with sunlight 2Zebrafish -- the stars of biomedicine 2